Predicting Radiation Side Effects – Prostox Webinar with interesting updates!

Predicting Radiation Side Effects – Prostox Webinar with interesting updates!

Last year, we presented a webinar on predicting radiation side effects with PROSTOX before treatment begins. PROSTOX works not just for first-time radiation but for recurrence and maybe even radioligand therapy like Pluvicto. By analyzing your unique genetics, you can make smarter, more informed decisions to avoid side effects and safeguard your quality of life for years to come.

PROSTOX Standard (previously PROSTOX CFRT+) predicts late grade ≥2 toxicity from conventionally fractionated (CFRT) or moderately hypofractionated (MHFRT) radiation therapy for patients with localized prostate cancer. Together with PROSTOX Ultra, which is already available for patients considering stereotactic body radiation therapy (SBRT), the PROSTOX portfolio now provides risk assessment across a broader range of external beam radiation therapy (EBRT) types. We’ll discuss the updates and other patient concerns, such as insurance coverage and questions to bring to your doctors.

Join us on April 27th, 2026, for a special presentation by Dr. Weidhaas: Predicting Radiation Side Effects – Prostox Updates! with Dr. Joanne Weidhaas, developer of the Prostox test

In the Ancan Barniskis Room (www.gotomeet.me/AnswerCancer) from 7:00 – 7:55 pm EST.